Corcept Therapeutics (CORT) Free Cash Flow (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Free Cash Flow data on file, last reported at -$17.0 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 463.76% year-over-year to -$17.0 million; the trailing twelve-month figure through Mar 2026 stood at $120.1 million (down 32.13% YoY), and the FY2025 full-year result was $141.8 million, down 27.71% from the prior year.
• Free Cash Flow retreated to -$17.0 million in Q1 2026, from $38.4 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $71.7 million in Q3 2024 to a low of -$17.0 million in Q1 2026.
• A 5-year average of $33.4 million and a median of $35.2 million in 2022 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow surged 984.05% in 2024 and sank 463.76% in 2026, its largest moves.
• Tracing CORT's Free Cash Flow over 5 years: stood at $33.4 million in 2022, then sank by 83.42% to $5.5 million in 2023, then surged by 984.05% to $59.9 million in 2024, then sank by 35.94% to $38.4 million in 2025, then plunged by 144.2% to -$17.0 million in 2026.
• Business Quant data shows CORT's Free Cash Flow at -$17.0 million in Q1 2026, $38.4 million in Q4 2025, and $54.5 million in Q3 2025.